Cleveland Clinic Cancer Center (Taussig) Outcomes
Breast Cancer
Breast Cancer Treatment
Cleveland Clinic's Breast Cancer Program is committed to providing patients with the best possible prevention, detection, and treatment options for breast disease. Breast cancer patients throughout main campus, regional hospitals and family health centers all received standardized care through care path guides and tumor board review. A multidisciplinary team comprising radiologists, pathologists, surgeons, plastic surgeons, medical oncologists, radiation oncologists, nurses, genetic counselors, psychologists, physical therapists, and social workers collaborates with each patient to develop a tailored care plan at National Accreditation Program for Breast Centers accredited sites throughout northeast Ohio.
Five-Year Overall Survival of Female Patients With All Stagesᵃ of Breast Cancer (N = 12552)
2011-2021
ᵃAJCC stage I-IV breast cancer
Five-Year Overall Survival of Female Patients With Breast Cancer by Raceᵃ (N = 12146)
2011-2021
| Number at Risk | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 |
|---|---|---|---|---|---|
| Caucasian (N = 10553) | 8762 | 7526 | 6037 | 4696 | 3394 |
| African-American (N = 1593) | 1305 | 1111 | 875 | 675 | 477 |
ᵃSelf-Reported
Five-Year Overall Survival of Female Patients With Breast Cancer by Hormone Receptor Status (N = 9988)
2011-2021
| Number at Risk | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 |
|---|---|---|---|---|---|
| ER/PR Negative (N = 1920) | 1625 | 1362 | 1132 | 893 | 669 |
| ER/PR Positive (N = 8056) | 6825 | 6039 | 5084 | 4059 | 3043 |
ER= estrogen receptor, PR= progesterone receptor
Five-Year Overall Survival of Female Patients With Breast Cancer by HER2 Status (N = 10285)
2011-2021
| Number at Risk | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 |
|---|---|---|---|---|---|
| HER2 Negative (N = 8729) | 7244 | 6253 | 5130 | 3986 | 2964 |
| HER2 Positive (N = 1556) | 1358 | 1191 | 1007 | 815 | 610 |
HER2= human epidermal growth factor receptor 2
Five-Year Overall Survival of Female Patients With Stages I-III Breast Cancer by Estrogen Receptor, Progesterone Receptor, and HER2 Status (N = 9454)
2011-2021
| Number at Risk | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 |
|---|---|---|---|---|---|
| ER/PR Positive (N = 6995) | 5824 | 5143 | 4327 | 3440 | 2542 |
| HER2 Positive (N = 1336) | 1177 | 1043 | 890 | 727 | 548 |
| Triple-Negative (N = 1123) | 944 | 781 | 635 | 491 | 362 |
ER= estrogen receptor, HER2= human epidermal growth factor receptor 2, PR= progesterone receptor
Five-Year Overall Survival of Female Patients With Stage IV Breast Cancer by Estrogen Receptor, Progesterone Receptor, and HER2 Status (N = 544)
2011-2021
| Number at Risk | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 |
|---|---|---|---|---|---|
| ER/PR Positive (N = 341) | 254 | 203 | 134 | 90 | 61 |
| HER2 Positive (N = 133) | 99 | 76 | 51 | 36 | 26 |
| Triple Negative (N = 70) | 34 | 19 | 13 | 9 | 4 |
ER= estrogen receptor, HER2= human epidermal growth factor receptor 2, PR= progesterone receptor
Five-Year Overall Survival of Female Patients With Stageᵃ 0 and I Breast Cancer (N = 7942)
2011-2021
| Number at Risk | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 |
|---|---|---|---|---|---|
| Stage 0 CC (N = 1965) | 1681 | 1497 | 1240 | 1000 | 751 |
| Stage I CC (N = 5977) | 4821 | 4113 | 3214 | 2462 | 1823 |
CC= Cleveland Clinic, NCDB= National Cancer Database
ᵃAJCC stage I-IV breast cancer
ᵇReference group data from the National Cancer Database (Commission on Cancer of the American College of Surgeons and the American Cancer Society) 2000-2002, as reported in: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer Science & Business Media; 2010.
Five-Year Overall Survival of Female Patients With Stageᵃ IIA and IIB Breast Cancer (N = 3608)
2011-2021
| Number at Risk | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 |
|---|---|---|---|---|---|
| Stage IIA (N = 2455) | 2186 | 1963 | 1696 | 1377 | 974 |
| Stage IIB (N = 1153) | 1007 | 868 | 728 | 574 | 411 |
CC= Cleveland Clinic, NCDB= National Cancer Database
ᵃAJCC stage I-IV breast cancer
ᵇReference group data from the National Cancer Database (Commission on Cancer of the American College of Surgeons and the American Cancer Society) 2000-2002, as reported in: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer Science & Business Media; 2010.
Five-Year Overall Survival of Female Patients With Stageᵃ IIIA and IIIB Breast Cancer (N = 937)
2011-2021
| Number at Risk | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 |
|---|---|---|---|---|---|
| Stage IIIA (N = 602) | 532 | 462 | 386 | 299 | 203 |
| Stage IIIB (N = 335) | 254 | 191 | 125 | 79 | 58 |
CC= Cleveland Clinic, NCDB= National Cancer Database
ᵃAJCC stage I-IV breast cancer
ᵇReference group data from the National Cancer Database (Commission on Cancer of the American College of Surgeons and the American Cancer Society) 2000-2002, as reported in: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer Science & Business Media; 2010.
Five-Year Overall Survival of Female Patients With Late-Stage Breast Cancer (N = 1287)
2012-2022
| Number at Risk | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 |
|---|---|---|---|---|---|
| Stage IIIC (N = 298) | 175 | 137 | 108 | 92 | 67 |
| Stage IV (N = 989) | 429 | 317 | 213 | 143 | 99 |
CC = Cleveland Clinic, NCDB = National Cancer Database
ᵃAJCC stage I-IV breast cancer
ᵇReference group data from the National Cancer Database (Commission on Cancer of the American College of Surgeon and the American Cancer Society) 2000-2002, as reported in: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer Science & Business Media; 2010
